SMS Pharmaceuticals Ltd Q1 FY2024 Concall Summary

Source transcript PDF: https://assets.stockscans.in/docs/93oa0xt40p3fmbk6itazytvg.pdf

Key Takeaways


Ibuprofen: The Big Bet

Vamsi Krishna: “It's a process, it's a very age old molecule, where it's not very easy to penetrate into various markets where we are trying our level best to push it with the resources that we currently have.”

Segment Health & Recovery

SegmentTrendCommentary
Ibuprofen▲ GrowingEncouraging progress across all markets; monthly sales and volume uptick on new approvals.
ARV▲ RecoveringAbsent in FY23, saw uptake in Q1 FY24; tender-based, good volumes expected for next couple of quarters.
Anti-diabetic▬ StableJV with Chemo; one of the largest exporters to Europe, collaboration expected to continue for next few quarters.
Antimigraine, Anti-ulcer, Anti-ED▬ StableOver two decades of presence; remarkable stability and devoted customer base.
Vamsi Krishna: “It's very difficult for us to you know envision how it's going to be in the next two - three years. But as of date it's the company for the next couple of quarters, I think we are envisioning good volumes on the ARV space as well.”

Margin & Return Profile

Vamsi Krishna: “So it'll take time again, as I mentioned, right? So by end of this year, I think we will be in a very, very good position because that's when our major products will take off in a very good phase.”

Capital Allocation & R&D

Vamsi Krishna: “around 70% of our R&D budget is dedicated to cost and process improvements of our existing products and towards backward integration of our existing high volume products and only around 30%, 35% we are looking at new product development.”

Market Focus & Geography


Guidance & Commitments

CommitmentSpecificsTimeline
Revenue & profit growth15–20% growth over FY23 in both top and bottom linesFY24
Operating marginSustained in line with present Q1 levelFY24
ROCEFull-year 10–12%; Q4 exit rate 15–17%FY24 / Q4 FY24
Ibuprofen market pictureClear picture on market position and approvalsBy end of FY24
Capacity utilizationFill current capacity to 75–80% before any Greenfield expansionNo date (condition-based)
Ibuprofen capacity expansionWait until existing capacity reaches 80–85% utilizationNo date (condition-based)
ARV volumesGood volumes expectedNext couple of quarters
Anti-diabetic collaborationExpected to continueNext few quarters

Key Metrics

MetricQ1 FY24
API segment revenue₹132.4 cr, 97.8% of consolidated revenue
Consolidated revenue growth guidance15% to 20% growth vs FY23, for full FY24
EBITDA margin19.4%, vs 20+% in previous year
EBIT~₹19 cr (per an analyst's math)
ROCE18%+, expected 18% to 19% range for full FY24
API export share85% of API segment revenue
API domestic share15% of API segment revenue
Ibuprofen revenue share~18% of total sales
Anti-diabetic revenue share24% of total sales
ARV revenue share~10% of total sales, projected 10% to 15% top-line contribution going forward
Anti-migraine revenue share19% of total sales
Anti-ulcer revenue share13% of total sales
Anti-inflammatory revenue share18% of total sales
Capacity utilization50% to 55%, target 75% to 80% before major expansion
Ibuprofen production capacity~700 metric tons per month, expandable to 1,200 metric tons per month